ID   SMS2_HUMAN              Reviewed;         365 AA.
AC   Q8NHU3; A8K2S9; B2RA61;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   15-MAR-2017, entry version 119.
DE   RecName: Full=Phosphatidylcholine:ceramide cholinephosphotransferase 2;
DE            EC=2.7.8.27;
DE   AltName: Full=Sphingomyelin synthase 2;
GN   Name=SGMS2; Synonyms=SMS2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAH28705.1};
RN   [1] {ECO:0000312|EMBL:AAP13352.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Kim N.-S., Shon H.-Y., Oh J.-H., Lee J.-Y., Kim J.-M., Hahn Y.,
RA   Park H.-S., Kim S., Kim Y.S.;
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4] {ECO:0000312|EMBL:AAP13352.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis {ECO:0000312|EMBL:AAH28705.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ENZYME REGULATION,
RP   AND TOPOLOGY OF C-TERMINUS.
RX   PubMed=14685263; DOI=10.1038/sj.emboj.7600034;
RA   Huitema K., Van Den Dikkenberg J., Brouwers J.F.H.M., Holthuis J.C.;
RT   "Identification of a family of animal sphingomyelin synthases.";
RL   EMBO J. 23:33-44(2004).
RN   [7]
RP   OVEREXPRESSION IN MOUSE.
RX   PubMed=16508036; DOI=10.1194/jlr.M600040-JLR200;
RA   Dong J., Liu J., Lou B., Li Z., Ye X., Wu M., Jiang X.-C.;
RT   "Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2
RT   increases the atherogenic potential in mice.";
RL   J. Lipid Res. 47:1307-1314(2006).
RN   [8]
RP   FUNCTION.
RX   PubMed=17449912; DOI=10.1074/jbc.M702423200;
RA   Tafesse F.G., Huitema K., Hermansson M., van der Poel S.,
RA   van den Dikkenberg J., Uphoff A., Somerharju P., Holthuis J.C.M.;
RT   "Both sphingomyelin synthases SMS1 and SMS2 are required for
RT   sphingomyelin homeostasis and growth in human HeLa cells.";
RL   J. Biol. Chem. 282:17537-17547(2007).
RN   [9]
RP   ACTIVE SITES, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-227;
RP   HIS-229; HIS-272 AND ASP-276.
RX   PubMed=18694848; DOI=10.1016/j.bbalip.2008.07.002;
RA   Yeang C., Varshney S., Wang R., Zhang Y., Ye D., Jiang X.C.;
RT   "The domain responsible for sphingomyelin synthase (SMS) activity.";
RL   Biochim. Biophys. Acta 1781:610-617(2008).
RN   [10]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-331; CYS-332; CYS-343 AND
RP   CYS-348, AND MUTAGENESIS OF 331-CYS-CYS-332; CYS-343 AND CYS-348.
RX   PubMed=19233134; DOI=10.1016/j.bbrc.2009.02.063;
RA   Tani M., Kuge O.;
RT   "Sphingomyelin synthase 2 is palmitoylated at the COOH-terminal tail,
RT   which is involved in its localization in plasma membranes.";
RL   Biochem. Biophys. Res. Commun. 381:328-332(2009).
CC   -!- FUNCTION: Sphingomyelin synthases synthesize the sphingolipid,
CC       sphingomyelin, through transfer of the phosphatidyl head group,
CC       phosphatidylcholine, on to the primary hydroxyl of ceramide. The
CC       reaction is bidirectional depending on the respective levels of
CC       the sphingolipid and ceramide. Plasma membrane SMS2 can also
CC       convert phosphatidylethanolamine (PE) to ceramide
CC       phosphatidylethanolamine (CPE). Major form in liver. Required for
CC       cell growth in certain cell types. Regulator of cell surface
CC       levels of ceramide, an important mediator of signal transduction
CC       and apoptosis. Regulation of sphingomyelin (SM) levels at the cell
CC       surface affects insulin sensitivity. {ECO:0000269|PubMed:14685263,
CC       ECO:0000269|PubMed:17449912}.
CC   -!- CATALYTIC ACTIVITY: A ceramide + a phosphatidylcholine = a
CC       sphingomyelin + a 1,2-diacyl-sn-glycerol.
CC   -!- ENZYME REGULATION: Inhibited by bacterial PC-phospholipase C
CC       inhibitor D609. {ECO:0000269|PubMed:14685263}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Golgi apparatus membrane; Multi-pass membrane protein.
CC       Note=Predominantly plasma membrane, some in Golgi apparatus. Some
CC       localization in the perinuclear region where it colocalizes with a
CC       sialyltransferase.
CC   -!- TISSUE SPECIFICITY: Brain, heart, kidney, liver, muscle and
CC       stomach. Also expressed in a number of cell lines such as
CC       carcinoma HeLa cells, hepatoma Hep-G2 cells, and colon carcinoma
CC       Caco-2 cells. {ECO:0000269|PubMed:14685263}.
CC   -!- PTM: Palmitoylated on Cys-331, Cys-332, Cys-343 and Cys-348; which
CC       plays an important role in plasma membrane localization.
CC       {ECO:0000269|PubMed:19233134}.
CC   -!- MISCELLANEOUS: Overexpression of the human protein in mouse causes
CC       increased non-HDL-sphingomyelin and non-HDL cholesterol levels,
CC       decreased HDL-sphingomyelin and HDL-cholesterol levels and
CC       increases lipoprotein atherogenic potential.
CC   -!- SIMILARITY: Belongs to the sphingomyelin synthase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF452717; AAP13352.1; -; mRNA.
DR   EMBL; AK290344; BAF83033.1; -; mRNA.
DR   EMBL; AK314049; BAG36758.1; -; mRNA.
DR   EMBL; CH471057; EAX06211.1; -; Genomic_DNA.
DR   EMBL; BC028705; AAH28705.1; -; mRNA.
DR   EMBL; BC041369; AAH41369.1; -; mRNA.
DR   EMBL; AC096564; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS3677.1; -.
DR   RefSeq; NP_001129729.1; NM_001136257.1.
DR   RefSeq; NP_001129730.1; NM_001136258.1.
DR   RefSeq; NP_689834.1; NM_152621.5.
DR   RefSeq; XP_011530000.1; XM_011531698.2.
DR   RefSeq; XP_011530001.1; XM_011531699.2.
DR   RefSeq; XP_011530002.1; XM_011531700.2.
DR   RefSeq; XP_011530003.1; XM_011531701.2.
DR   RefSeq; XP_011530004.1; XM_011531702.2.
DR   RefSeq; XP_016863328.1; XM_017007839.1.
DR   RefSeq; XP_016863329.1; XM_017007840.1.
DR   UniGene; Hs.595423; -.
DR   ProteinModelPortal; Q8NHU3; -.
DR   BioGrid; 127938; 8.
DR   IntAct; Q8NHU3; 10.
DR   STRING; 9606.ENSP00000351981; -.
DR   BindingDB; Q8NHU3; -.
DR   ChEMBL; CHEMBL3112379; -.
DR   GuidetoPHARMACOLOGY; 2521; -.
DR   SwissLipids; SLP:000000172; -.
DR   iPTMnet; Q8NHU3; -.
DR   PhosphoSitePlus; Q8NHU3; -.
DR   BioMuta; SGMS2; -.
DR   DMDM; 44888519; -.
DR   MaxQB; Q8NHU3; -.
DR   PaxDb; Q8NHU3; -.
DR   PeptideAtlas; Q8NHU3; -.
DR   PRIDE; Q8NHU3; -.
DR   Ensembl; ENST00000359079; ENSP00000351981; ENSG00000164023.
DR   Ensembl; ENST00000394684; ENSP00000378176; ENSG00000164023.
DR   Ensembl; ENST00000394686; ENSP00000378178; ENSG00000164023.
DR   GeneID; 166929; -.
DR   KEGG; hsa:166929; -.
DR   UCSC; uc003hyl.6; human.
DR   CTD; 166929; -.
DR   DisGeNET; 166929; -.
DR   GeneCards; SGMS2; -.
DR   HGNC; HGNC:28395; SGMS2.
DR   HPA; HPA015076; -.
DR   MIM; 611574; gene.
DR   neXtProt; NX_Q8NHU3; -.
DR   OpenTargets; ENSG00000164023; -.
DR   PharmGKB; PA162403069; -.
DR   eggNOG; KOG3058; Eukaryota.
DR   eggNOG; ENOG410XNSC; LUCA.
DR   GeneTree; ENSGT00390000001630; -.
DR   HOGENOM; HOG000233822; -.
DR   HOVERGEN; HBG048216; -.
DR   InParanoid; Q8NHU3; -.
DR   KO; K04714; -.
DR   OMA; VIVAYYI; -.
DR   OrthoDB; EOG091G0J6C; -.
DR   PhylomeDB; Q8NHU3; -.
DR   TreeFam; TF314547; -.
DR   BRENDA; 2.7.8.27; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   GenomeRNAi; 166929; -.
DR   PRO; PR:Q8NHU3; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000164023; -.
DR   CleanEx; HS_SGMS2; -.
DR   ExpressionAtlas; Q8NHU3; baseline and differential.
DR   Genevisible; Q8NHU3; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0047493; F:ceramide cholinephosphotransferase activity; IDA:UniProtKB.
DR   GO; GO:0002950; F:ceramide phosphoethanolamine synthase activity; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0033188; F:sphingomyelin synthase activity; IBA:GO_Central.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IBA:GO_Central.
DR   GO; GO:1905373; P:ceramide phosphoethanolamine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006686; P:sphingomyelin biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR025749; Sphingomyelin_synth-like_dom.
DR   Pfam; PF14360; PAP2_C; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Golgi apparatus; Kinase;
KW   Lipid metabolism; Lipoprotein; Membrane; Palmitate; Polymorphism;
KW   Reference proteome; Sphingolipid metabolism; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    365       Phosphatidylcholine:ceramide
FT                                cholinephosphotransferase 2.
FT                                /FTId=PRO_0000221072.
FT   TRANSMEM     80    100       Helical. {ECO:0000255}.
FT   TRANSMEM    128    148       Helical. {ECO:0000255}.
FT   TRANSMEM    159    179       Helical. {ECO:0000255}.
FT   TRANSMEM    206    226       Helical. {ECO:0000255}.
FT   TRANSMEM    248    268       Helical. {ECO:0000255}.
FT   TRANSMEM    275    295       Helical. {ECO:0000255}.
FT   TOPO_DOM    296    365       Cytoplasmic. {ECO:0000255}.
FT   ACT_SITE    229    229       {ECO:0000269|PubMed:18694848}.
FT   ACT_SITE    272    272       {ECO:0000269|PubMed:18694848}.
FT   ACT_SITE    276    276       {ECO:0000269|PubMed:18694848}.
FT   LIPID       331    331       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:19233134}.
FT   LIPID       332    332       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:19233134}.
FT   LIPID       343    343       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:19233134}.
FT   LIPID       348    348       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:19233134}.
FT   VARIANT      21     21       T -> M (in dbSNP:rs17038204).
FT                                /FTId=VAR_052025.
FT   MUTAGEN     227    227       S->A: Abolishes enzyme activity by about
FT                                70%. No change in subcellular location.
FT                                {ECO:0000269|PubMed:18694848}.
FT   MUTAGEN     229    229       H->A: Completely abolishes enzyme
FT                                activity. No change in subcellular
FT                                location. {ECO:0000269|PubMed:18694848}.
FT   MUTAGEN     272    272       H->A: Completely abolishes enzyme
FT                                activity. No change in subcellular
FT                                location. {ECO:0000269|PubMed:18694848}.
FT   MUTAGEN     276    276       D->A: Completely abolishes enzyme
FT                                activity. No change in subcellular
FT                                location. {ECO:0000269|PubMed:18694848}.
FT   MUTAGEN     331    332       CC->AA: Little effect on palmitoylation;
FT                                when associated with A-343 or A-348.
FT                                Abolishes palmitoylation and dramatically
FT                                reduces plasma membrane localization;
FT                                when associated with A-343 and A-348.
FT                                {ECO:0000269|PubMed:19233134}.
FT   MUTAGEN     343    343       C->A: Strongly decreases palmitoylation;
FT                                when associated with A-348. Abolishes
FT                                palmitoylation and dramatically reduces
FT                                plasma membrane localization; when
FT                                associated with 331-A-A-332 and A-348.
FT                                {ECO:0000269|PubMed:19233134}.
FT   MUTAGEN     348    348       C->A: Strongly decreases palmitoylation;
FT                                when associated with A-343. Abolishes
FT                                palmitoylation and dramatically reduces
FT                                plasma membrane localization; when
FT                                associated with 331-A-A-332 and A-343.
FT                                {ECO:0000269|PubMed:19233134}.
FT   CONFLICT    313    313       W -> R (in Ref. 2; BAF83033).
FT                                {ECO:0000305}.
SQ   SEQUENCE   365 AA;  42280 MW;  49B3560AFB87CF40 CRC64;
     MDIIETAKLE EHLENQPSDP TNTYARPAEP VEEENKNGNG KPKSLSSGLR KGTKKYPDYI
     QIAMPTESRN KFPLEWWKTG IAFIYAVFNL VLTTVMITVV HERVPPKELS PPLPDKFFDY
     IDRVKWAFSV SEINGIILVG LWITQWLFLR YKSIVGRRFC FIIGTLYLYR CITMYVTTLP
     VPGMHFQCAP KLNGDSQAKV QRILRLISGG GLSITGSHIL CGDFLFSGHT VTLTLTYLFI
     KEYSPRHFWW YHLICWLLSA AGIICILVAH EHYTIDVIIA YYITTRLFWW YHSMANEKNL
     KVSSQTNFLS RAWWFPIFYF FEKNVQGSIP CCFSWPLSWP PGCFKSSCKK YSRVQKIGED
     NEKST
//
